Evzio®
(naloxone HCl injection)
2 mg auto-injector

DO NOT HESITATE. MAKE SURE YOUR CUSTOMERS ARE EVZIO-READY

EVZIO—an auto-injector designed to be easy to use—provides simple, on-the-spot voice and visual guidance to help those most likely to be the first to witness an opioid overdose administer naloxone. **EVZIO is not a substitute for emergency medical care.**

EVZIO Is Designed to Be...

EASY TO USE

- Voice and visual guidance that may help make it easy for first responders or those non-medically trained to administer naloxone during an opioid overdose
- Prefilled auto-injector is used to administer naloxone in the outer thigh through clothing if necessary (even blue jeans), whether face up or face down

EASY TO CARRY

- Small enough to fit in most pockets so it can be on hand at all times in case of an opioid overdose

Be EVZIO-Ready

Provide EVZIO as an important part of an opioid overdose plan.

PATIENTS SHOULD SEEK EMERGENCY MEDICAL ASSISTANCE IMMEDIATELY AFTER USE. THE USE OF EVZIO MAY RESULT IN SYMPTOMS OF ACUTE OPIOID WITHDRAWAL.

INDICATION

EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.

Seek emergency medical assistance immediately after use. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.

The following warnings and precautions should be taken when administering EVZIO:

- Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeated doses of naloxone using a new EVZIO, as necessary, while awaiting emergency medical assistance.
- Risk of Limited Efficacy With Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
- Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
- Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were most commonly observed in EVZIO clinical studies: dizziness and injection site erythema.

Please see additional Important Safety Information on back. Please see full Prescribing Information enclosed and at EVZIO.com.

Evzio®
(naloxone HCl injection)
2 mg auto-injector

DO NOT HESITATE. MAKE SURE YOUR CUSTOMERS ARE EVZIO-READY

EVZIO—an auto-injector designed to be easy to use—provides simple, on-the-spot voice and visual guidance to help those most likely to be the first to witness an opioid overdose administer naloxone. **EVZIO is not a substitute for emergency medical care.**

EVZIO Is Designed to Be...

EASY TO USE

- Voice and visual guidance that may help make it easy for first responders or those non-medically trained to administer naloxone during an opioid overdose
- Prefilled auto-injector is used to administer naloxone in the outer thigh through clothing if necessary (even blue jeans), whether face up or face down

EASY TO CARRY

- Small enough to fit in most pockets so it can be on hand at all times in case of an opioid overdose

INDICATION

EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.

Seek emergency medical assistance immediately after use. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.

The following warnings and precautions should be taken when administering EVZIO:

- Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeated doses of naloxone using a new EVZIO, as necessary, while awaiting emergency medical assistance.
- Risk of Limited Efficacy With Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
- Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
- Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were most commonly observed in EVZIO clinical studies: dizziness and injection site erythema.

Please see additional Important Safety Information on back. Please see full Prescribing Information enclosed and at EVZIO.com.

Evzio®
(naloxone HCl injection)
2 mg auto-injector

TAKE-HOME NALOXONE TECHNICAL OVERVIEW

Evzio®
(naloxone HCl injection)
2 mg auto-injector

NARCAN® (naloxone HCl)
NASAL SPRAY 4mg

Supplied - Carton containing two EVZIO (naloxone hydrochloride injection, USP) 2 mg auto-injectors and a single Trainer for EVZIO	**Supplied** - Carton containing four (4) blister packages each with a single spray device for the 2 mg and carton containing two (2) blister packages each with a single spray device for the 4 mg
Guided - Easy to follow voice and visual instructions	Instruction leaflet included
Pre-filled single-use auto-injector – does not need to be assembled or repackaged	Nasal spray; no assembly required
Storage: Store at room temperature 59°F to 77°F (15°C to 25°C). Excursions permitted up to 104°F (40°C).	**Storage:** Store at room temperature 59°F to 77°F (15°C to 25°C). Excursions permitted up to 104°F (40°C). Do not freeze. Protect from light.
Retractable needle – helps to prevent exposure to the needle before, during, and after injection	Needle free
Portable – small enough to fit into most pockets so it can be carried at all times	Store in the blister and cartons provided.
Slim – easily grasped with either hand by people with various hand sizes, facilitating proper injection orientation	
Durable – tested to withstand the rigors of use **Extreme temperatures:** Tested up to 6 months as high as 104°F (40°C) **Crushing:** Withstands up to 300 pound-force to the device **Chemical exposure:** Tested with window cleaner, soap, bleach, acetone, nail polish, hand sanitizer, stain remover liquid, and hydrogen peroxide **Liquid ingress:** Protects against water penetration (eg, heavy rain fall) and delivers its intended dose. Tested by exposing the auto-injector to falling drops of water at a rate of 1 mm/min for a 10-minute period	
Trainer provided with every pack	No trainer
Available in 2 mg dose	Available in 2 mg and 4 mg dose

A majority of states have enacted legislation that is supportive of administering aid for opioid-related overdoses, and some states even go so far as providing immunity for events leading up to assisting in such a crisis.

IMPORTANT SAFETY INFORMATION *(continued)*

Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated signs and symptoms of opioid withdrawal including: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In the neonate, opioid withdrawal signs and symptoms also included: convulsions, excessive crying, and hyperactive reflexes.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information enclosed and at EVZIO.com.

EVZIO.com